Exelixis | EXEL - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Amgen USD 4.78B 1.12B 2026-03
AstraZeneca USD 12.22B 4.04B 2026-06
Bayer EUR 9.88B 452M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cytokinetics USD 200.58M 4.46M 2026-03
Eisai JPY 215.74B 15.84B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Exelixis USD 359.47M 3.28M 2026-03
Genmab DKK 798M 235M 2025-12
Glaxosmithkline GBP 5.34B 3.83B 2026-03
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
MacroGenics USD 21.2M 32.13M 2026-03
Merck USD 18.17B 8.01B 2026-03
Moderna USD 960M 817M 2026-06
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novartis USD 10.2B 912M 2026-06
Pfizer USD 90.1B 77.19B 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sanofi EUR 8.98B 1.73B 2026-03
Takeda JPY 1.02T 89.68B 2026-06
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Xencor USD 82.38M 513K 2026-03